Story perspectives

Unlocking Brain Cancer: New Targets and Treatments Emerged

9/17/2025

Summary

Story summary

Nuclear receptors (NRs) are identified as underutilized targets in brain cancer treatment, impacting tumorigenesis and therapeutic resistance.
Androgen receptors (ARs) and estrogen receptors (ERs) affect glioblastoma survival and treatment responses, with specific inhibitors improving chemotherapy efficacy.
The study calls for extensive preclinical validation and clinical trials for NR-targeted therapies in neuro-oncology.
Long non-coding RNAs (lncRNAs) are highlighted as potential breast cancer biomarkers, with LINC00974 suggested for early detection.
Innovative delivery systems, such as the Vir-inspired Biotechnical Vector (VIBV), aim to improve RNA therapeutic precision in tumor targeting.

1 of 1

Story summary

Nuclear receptors (NRs) are identified as underutilized targets in brain cancer treatment, impacting tumorigenesis and therapeutic resistance.
Androgen receptors (ARs) and estrogen receptors (ERs) affect glioblastoma survival and treatment responses, with specific inhibitors improving chemotherapy efficacy.
The study calls for extensive preclinical validation and clinical trials for NR-targeted therapies in neuro-oncology.
Long non-coding RNAs (lncRNAs) are highlighted as potential breast cancer biomarkers, with LINC00974 suggested for early detection.
Innovative delivery systems, such as the Vir-inspired Biotechnical Vector (VIBV), aim to improve RNA therapeutic precision in tumor targeting.